ReviewAnnals of surgery1997
Barrett's esophagus. The significance of p53 in clinical practice.
Review in Annals of surgery, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- The Tissue Systems Pathology Test Predicts Risk of Progression in Patients With Barrett's Esophagus: Systematic Review and Meta-Analysis.Journal of clinical gastroenterology · 2026Pooled it
- The prognostic significance of p53 expression in gastric cancer: a meta-analysis.Journal of cancer research and clinical oncology · 2015Pooled it
- Deep muscularis propria tumor invasion without lymph node metastasis as a unique subclassification of stage IB gastric cancer: a retrospective study.BMC gastroenterology · 2022Article
- p53 staining correlates with tumor type and location in sebaceous neoplasms.The American Journal of dermatopathology · 2012Article
- [Barrett's esophagus. An update].Der Pathologe · 2012Review
- Risk factors for neoplastic progression in Barrett's esophagus.World journal of gastroenterology · 2011Review
- Increased p53 expression in the malignant transformation of Barrett's esophagus is accompanied by an upward shift of the proliferative compartment.Pathology oncology research : POR · 2009Article
- Molecular analysis of the p53 gene in patients with intestinal metaplasia of the cardia and Barrett's esophagus: characterization by sequencing.Digestive diseases and sciences · 2007Article
- Diagnosis and grading of dysplasia in Barrett's oesophagus.Journal of clinical pathology · 2006Review
- Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients manuscript id: 8962091628764582.BMC cancer · 2006Article
- Mutations of p53 gene exons 4-8 in human esophageal cancer.World journal of gastroenterology · 2005Article
- Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia.The American journal of pathology · 2001Article
- Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia.Annals of surgery · 2000Article
- Role of p53 assessment in management of Barrett's esophagus.Digestive diseases and sciences · 1999Review
- Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region.The American journal of pathology · 1998Article
- Carcinogen 4-Nitroquinoline Oxide (4-NQO) Induces Oncostatin-M (OSM) in Esophageal Cells.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe authors provide an updated review the molecular biology of the p53 tumor suppressor gene with reference to its role in the malignant degeneration of Barrett's esophagus. SUMMARY BACKGROUND DATA: Appreciation of the function of the tumor suppressor gene p53 has given new insight into regulation of the cell cycle, and the gene appears to play an important role in many solid tumors. Esophageal adenocarcinoma is increasing in frequency in the western world at an alarming rate and is unique because there is a clear metaplasia (Barrett's mucosa)/ dysplasia/carcinoma sequence. p53 malfunction arises as an early event in this carcinogenic process and has been demonstrated in patients with nondysplastic Barrett's metaplasia. The possible causes of p53 malfunction in this setting are discussed. The most reliable method for the detection of p53 mutations is DNA sequencing. p53 immunohistochemistry appears too insensitive to act as a reliable marker for the presence of a mutation and cannot be used as a reliable marker for the future development of cancer.
conclusionsHigh-grade dysplasia within Barrett's mucosa remains the best clinical predictor of adenocarcinoma. The mutational spectrum observed in these tumors should provide clues to their etiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.